2013-11-14 14:30:00 CET

2013-11-14 14:30:48 CET


REGULATED INFORMATION

English
Biotie Therapies - Major shareholder announcements

Biotie: Notification according to Chapter 9, Section 10 of the Finnish Securities Market Act


BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 14 November 2013 at 3.30 pm.

Notification according to Chapter 9, Section 10 of the Finnish Securities Market
Act

Biotie Therapies Corp. ("Company" or "Biotie") has gained knowledge of a
notification regarding changes in number of votes in accordance with Chapter 9,
Section 5 of the Finnish Securities Markets Act, described below.

The notification received by the Company concerns the changes in holdings of the
Company's shares by Novo A/S as a result of the transactions carried out on 13
November 2013. As a result of these transactions, the aggregate holding of Novo
A/S has decreased below 5 per cent of the total number of shares and votes of
the Company.

The change in holdings in accordance with Chapter 9, Section 5 of the Finnish
Securities Markets Act of which the Company has gained knowledge of is described
below:

Name     Number of shares    Number of shares    (%) of shares   (%) of voting
         and voting rights   and voting rights   after           rights after
         before              after

Novo A/S 26,141,552          17,441,554          3.85%           3.91%


The registered number of shares in Biotie Therapies Corp. is 452,710,738. Of
these shares 6,509,351 are held by the Company and the number of outstanding
shares and voting rights attached to the shares amounts thus to 446,201,387.

Turku, 14 November 2013

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information please contact:

David Cook
CFO
email: david.cook@biotie.com

Tel: +358 2 2748 900

Virve Nurmi
Investor Relations Manager
email: virve.nurmi@biotie.com

Tel: +358 2 2748 911

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com


[HUG#1743250]